INTRODUCTION
Disease prevention has been of paramount importance to clinicians for over 200 years. Epidemiological studies have focused on decreasing water-and airborne pathogens and development of drugs and vaccines. [1] However, in the late 20 th century, significant advancements have been made in molecular medicine and this has led to a paradigm shift towards personalized medicine. Effective point-of-care treatment requires identification of biomarkers for early disease detection and effective therapeutic intervention. [2] This review discusses the potential use of saliva as an alternate diagnostic medium and the advancements made in the field of mass spectrometry in global discovery of potential biomarkers and subsequent validation for early cancer detection and diagnosis.
BIOMARKER APPLICATION IN CANCER
Biomarkers can be defined as a measurable indicators of cellular, biochemical, or molecular changes between normal and abnormal biological processes detectable in tissue or body fluids. [3, 4] A biomarker may be classified as: (1) serve as an indicator of risk of developing disease, (2) identify subjects with sub-clinical disease, (3) aid in diagnosing apparent disease, (4) establish disease severity, and (5) predict disease prognosis. [5] Thus, due to its wide-spread application, the field of biomarker research has gained significant momentum amongst academic researchers, clinicians and the pharmaceutical industry for different diseases such as cancer, [6, 7] Alzheimer's, [8] leptospirosis [9] and autoimmune diseases.
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Cancer is the second most leading cause of death in the United States. [3, 12] Cancer can be controlled by local therapy when the primary tumor is localized and detected early, but the survival rate decreases once it has metastasized to different organs. [13] For example, the survival rate of oral squamous cell carcinoma (OSCC) has been static over the last 30 years; however, if the malignancy is detected early, the survival rate goes as high as 80% with effective treatment. [6] Currently, the gold standard for diagnosis of cancer (e.g. OSCC) is based on incisional biopsies coupled with histological analysis. [14, 15] Nevertheless, a biopsy has its limitations, e.g. pain and discomfort, making it almost impossible to obtain repeated biopsies from suspected or confirmed subjects. Thus, it is imperative to develop strategies to detect the disease early, when not clinically apparent, to limit human suffering, burgeoning cost and emotional stress. A large number of biomarkers would be expected in clinical application considering the thousands of articles published claiming to have identified biomarkers in cancer diagnosis. However, translating these discoveries to clinically-relevant assays has been difficult. Indeed, less than 30 cancer biomarkers have been approved to date by the Food and Drug Administration (FDA), with most of the biomarkers being used are for monitoring response to therapy. [4] This slow pace of biomarker translation can be attributed, but not limited, to a flawed discovery process, lack of continuation by individual researchers, limitation of samples and no follow-up data to identify and design effective diagnostics. [3, 4] 
SOURCES OF BIOMARKERS
Historically, blood has been the primary diagnostic medium. [4] Consequently, assays routinely measure over 100 different blood analytes in the laboratory setting. [16] However, the complexities of blood pose a serious bottleneck for analyte detection of low abundant proteins. [17] Thus, it is imperative to explore different diagnostic media such as stool, urine, sputum and saliva for biomarker detection as they could have elevated concentrations of biomarkers relative to blood. [18] In the context of this review, saliva will be discussed as a diagnostic medium.
Saliva
Saliva is a clear, slightly acidic (pH: 6-7) complex biological fluid composed of secretions from three major salivary glands (parotid, submandibular and sublingual) [19] and minor salivary glands located in the lower lip, tongue, palate, cheeks and pharynx. [20] Saliva is an isotonic fluid with thousands of proteins. [21] The majority (~80%) of these proteins are secreted by acinar cells, [22] with ductal cells contributing approximately ~20%. [3] Proteins are stored in high concentration in acinar cells and released via secretory pathway (regulated or constitutive) or to lysosomes for degradation. [23, 24] In addition, exosomes, small 'cup-shaped', 30-100 nm diameter membrane vesicles which contain ubiquitous and cell-specific proteins [25] are secreted into saliva. Along with proteins, ions such as Na + and Cl -are secreted by acinar cells into the lumen of the gland. Majority of the Na + and Cl -is re-absorbed while additional proteins, K + and HCO3 -ions are secreted. [24, 26, 27] Figure 1 shows the secretion of proteins and ions by acinar and ductal cells into salivary gland ducts.
Similar to blood, saliva contains a variety of enzymes, hormones, antibodies, growth factors and antimicrobial constituents. These proteins aid in multiple functions such as digestion, food swallowing and tasting, lubrication, tooth mineralization, pH buffering and maintenance of general health by interacting with oral microbiota. [28] Saliva constituents may originate from the salivary glands or are filtered from blood by transcellular or paracellular routes. [29] Thus, the many similarities in salivary composition with blood strongly suggest that it mirrors the physiological In acinar cells, proteins are transported from the endoplasmic reticulum to the Golgi, where they are sorted into granules of the regulated and constitutive secretion pathways for exocytosis. In addition, exosomes containing proteins are released into the extracellular space by fusion of vesicles with the plasma membrane. Similarly, Na + and Cl -are secreted into the lumen by transcellular transport mechanisms and paracellular pathway from blood. While saliva passes through the ducts, the majority of the Na + and Cl -is re-absorbed while additional proteins, K + and HCO3 -ions are secreted to make up the final composition of saliva. ER = endoplasmic reticulum, GC = Golgi complex, CS = constitutive secretion, RS = regulated secretion, E = exosome.
state of the body including systemic and local illness. [30, 31] Furthermore, saliva collection is easy, requires little equipment and training, and is noninvasive, thereby eliminating the anxiety and discomfort associated with blood collection. Due to these advantages, saliva has gained momentum as a diagnostic biofluid in the post-genomic era. It has been used by researchers to detect changes in protein abundance associated with age in healthy individuals, [32] in different metabolic, [33] and autoimmune [10, 11] disease states. More specifically, salivary proteins such as S100A8 and quinone reductase in oral squamous cell carcinoma, [6] annexin A1 and beta-and gamma actin in head and neck cancer, [34] and PSP94 and CRISP-3 for prostate cancer have been used as diagnostic markers. [35] However, salivary analytes generally present at lower concentrations than found in blood raises concerns about the limits of detection. Importantly, significant advancements have been made to combine sensitive proteomics with emerging molecular techniques, and to take advantage of dedicated resources such as Salivaomics Knowledge Base (SKB) to disseminate the potential use of saliva as a diagnostic medium. [3] 
PROTEIN BIOMARKERS AND PROTEOMICS
Tumor development is a complex process where proteins are actively secreted or released into the circulation by affected cells due to necrosis or apoptosis. Tumorigenesis involves different signal pathways and cell types that require numerous protein-protein and protein-DNA interactions at the epigenetic, transcriptional and translational levels. Thus, in the truest functional sense, cancer is considered a proteomic disease. [36, 37] Consequently, protein biomarkers for early cancer diagnosis using the "state-of-the-art" mass spectrometry technology can provide complementary information to genomics. Furthermore, proteomics cannot only detect novel proteins [38] and changes in protein abundance between normal and malignant cells, [7] but also identify different post-translational modifications (PTMs) and to what degree they are modified in disease states. [39] Until recently, two dimensional gel electrophoresis (2DE-PAGE) and differential gel electrophoresis (2DE-DIGE) techniques have been the most widely used technique to obtain best snapshot of the proteins expressed in a cell or body fluid. [7, 40] The gel based approach offers a couple of advantages such as the ability to separate different protein isoforms, post-translationally modified proteins and detect extensive sample degradation. However, this technology has limitations such as restricted dynamic range, poor reproducibility, and loss of transmembrane proteins [41, 42] in addition to being low-throughput, labor intensive and time consuming. Subsequently, solution-based isoelectric focusing has been performed with success, although transmembrane proteins remained under-represented. [42] Consequently, to overcome these technical limitations, researchers have performed in-solution digestion of proteins followed by analyzing the samples using liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) for global discovery and subsequent validation for early and improved disease diagnosis.
MASS SPECTROMETRY
The primary proteomic technology used for biomarker discovery and quantification is mass spectrometry. There are two general strategies by which proteins can be identified using mass spectrometry: (1) analyzing complex mixtures of proteins based on peptides, commonly referred to as the "bottom-up approach" and, (2) whole protein analysis known as the "top-down approach". However, the main aim of these approaches was protein and/or PTM identification; but, with more recent advances in mass spectrometry and bioinformatics, there has been shift to more quantitative mass spectrometry where an identified protein and/or PTM can also be relatively quantified between samples (e.g. normal vs. malignant). For quantification of proteins, either label-free or stable isotope labeling is performed. The use of stable-isotopically labeled peptides enables also absolute quantification of proteins which is very often utilized in the verification stage of biomarker discovery.
Fractionation and protein identification
To increase the likelihood of discovering potential biomarkers and maximize protein identifications, it is crucial to reduce the complexity of the sample by fractionation or by depletion of abundant proteins, allowing for the identification of medium and low copy proteins. Fractionation can be performed either at the protein or peptide level. Different depletion strategies have been used to separate abundant proteins in body fluids such as plasma, saliva and urine. For example, immunoaffinity, [43, 44] solvent solubilization, [45] and hydrophobic interaction [46] have been used in plasma. Similarly, ion exchange, affinity, reversed-phase (RP), gel-filtration, hydrophobic charge interaction and lectin chromatography [21, 32, 38, 47] have been reported for salivary proteins. For urinary proteins, strategies such as ultrafiltration, [48] microfiltration [49] and multi protein immuno-affinity columns [48, 50] have been successful. It should be noted that there is no single fractionation strategy superior to others; therefore this has to be empirically determined for each sample and experiment. Furthermore, both bound and depleted fractions should be analyzed as many proteins often bind to other proteins and peptides. [44, 51] For peptide separation before mass spectrometric detection, fractionation, reversed-phase (RP) chromatography is routinely used to separate peptide based on their hydrophobicity. [52] However, samples such as plasma have large dynamic protein ranges limiting identification. [53] Consequently, an additional fractionation step such as strong-cation exchange (SCX) can be employed to reduce complexity. [54] Two dimensional liquid chromatography (LC/LC) when placed in-line with mass spectrometer is called multidimensional protein identification technology (MudPIT). [41] This technology has been successfully used for identifying proteins, for example, in urine, [55, 56] and saliva. [21, 25, 32, 38] After injecting into the mass spectrometer and acquisition of peptide fragmentation spectra (MS/MS), peptide spectra are searched against species specific database using different algorithms such as SEQUEST, [57] MASCOT, [58] X!Tandem, [59] and Prolucid [60] for protein and peptide identifications.
Quantification
In addition to protein identifications, mass spectrometry can be used to quantify the differences in protein expression between samples. Mass spectrometry analysis can be performed either by label-free or isotope labeled approaches. The same approaches can be used to identify and quantify protein post-translational modifications (e.g. phosphorylation and acetylation).
Label-free quantification
The label-free approach can be performed either by spectral count (SC) or based on intensity. In the SC approach, a tandem mass spectrum for each peptide is used for identification and quantification of proteins. A number of studies have been performed using the SC-based approach in healthy subjects, [25, 32] cancer, [61] and biomarker discovery in Down syndrome. [62] In contrast, quantification using intensity-based approach takes ion intensity of each identified peptide by determining the peak area of the extracted ion chromatogram of each precursor ion. Thus, mass spectrometry ion intensity of peptide is used for relative quantification of that peptide between samples, for example, as used in drug safety studies for cytochrome P450 [63] and identification of biomarkers in Graft-versus-host disease. [11] 
Stable isotope quantification
Although the label-free approach is cheap and fast due to omission of labeling, there are systematic and random errors. [64] In contrast, labeling provides protein ratios that can be determined with better accuracy and precision as compared to label-free. By this latter approach, peptides labeled with heavy isotope are compared to peptides containing light isotopes in a mass spectrometer, generating a light/heavy ratio which can be used for relative quantification between samples.
The peptides can be labeled via metabolic incorporation into cell or tissue culture ( 15 N/ 14 N), [65] stable isotope labeling by amino acids in cell culture (SILAC), [66] amino group labeling using isotope-coded affinity tags (ICAT), [67] isobaric tags for relative and absolute quantification (iTRAQ), [68] tandem mass tags (TMT), [69] and enzymatically catalyzed incorporation ( 18 O labeling). [70] Metabolic, TMT, and SILAC labeling strategies have been used for a number of biomarker discovery studies. [71] [72] [73] Similarly, iTRAQ and 18 O labeling have been used for biomarker discovery in Parkinson's disease and hepatocellular carcinoma, respectively. [74, 75] Figure 2 shows the comparison of quantification strategies.
Isotopically labeled peptides can be used for absolute quantification. In this strategy, a known amount of heavyisotope-labeled peptides is mixed with complex peptide sample and subsequently protein concentration is calculated by comparing it to the labeled peptides. [76] 
Targeted quantification
Currently, ELISA and Western blots are the most commonly used techniques to quantify candidate proteins. Although these techniques are informative, there are limitations, such as the availability, sensitivity and specificity of antibodies for proteins, time and cost for development and multiplexing immunoassays in large patient populations. [77] With the advancement made in mass spectrometer sensitivity, targeted quantification of biomarker, either by label-free or isotope labeling, can be performed using triple-quadrupole mass spectrometers by single reaction monitoring (SRM) or multiple reaction monitoring (MRM). [74, 78] To this end, SRM has been successful in verifying proteins, for example, from breast cancer samples, [79] renal carcinoma, [74] and Down syndrome. [62] Fur-malignant cells. [85] Furthermore, using multiple biomarkers improves the predictive power of biomarkers as the combination of three aforementioned markers show a sensitivity of 88.5% and specificity of 92.3%. Similarly, the positive and negative predictive score of these three biomarkers to differentiate between patient and healthy subject was 92% and 88.9%, respectively. [81] For the first time, Xie et al [82] identified proteins extracted from cells present in whole saliva of oral squamous cell carcinoma (OSCC) patients and use of a novel fractionation strategy called as free flow electrophoresis (FFE) prior to analysis by mass spectrometry. The aim of the study was to gain insights into the potential use of this approach for the detection of proteins from OSCC patients. To this end, cells were collected from saliva of 4 patients and proteins were extracted from individual subjects for analysis. Furthermore, to maximize protein identification after trypsin digestion, peptides were subjected to FFE prior to SCX and RP separation. By this approach, 351 additional proteins were identified as opposed to when SCX and RP were employed for peptide fractionation prior to mass spectrometry. Amongst the identified proteins, Western blot was performed on select proteins based on their involvement either in transcriptional control in the development of OSCC (e.g. signal transducer and activator of transcription) or tumor marker that play a role in its progression (squamous cell carcinoma antigen 1).
In addition to LC-based mass spectrometric approach to analyze saliva, matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI) have been used for biomarker discovery. For example, saliva from oral cancer patients (20 patients and 20 controls) analyzed using MALDI identified upregulation of amylase and albumin in patient samples. [83] In a pilot study performed using SELDI, previously known salivary proteins (e.g. cystatins, albumin and lactoferrin) were confidently identified from breast cancer patients (3 patients and 3 controls). [84] Saliva cannot only be used as a diagnostic medium to detect putative biomarkers directly related to a disease (e.g. oral cancer), but it can also be used to identify proteins such as CA 125 detected in higher abundance in patients with ovarian cancer as post-treatment follow up. [86] Similarly, high concentrations of c-erbB-2 and epidermal growth factor (EGF) have also been detected in saliva as a post-operative follow-up for breast cancer. [87, 88] In label-free method, sample one (S1) and sample two (S2) are treated separately through the same processing steps for characterization. In contrast, in vitro labeling (e.g. isotope-coded affinity tags (ICAT), isobaric tags for relative and absolute quantification (iTRAQ) and tandem mass tags (TMT), tagged samples are mixed after enzymatic digestion for subsequent analysis; while in metabolic labeling samples are labeled by incorporating nonradioactive isotopic form of amino acids and mixed for further processing. All samples are analyzed by mass spectrometry to quantify differences in protein abundance. thermore, multiplexed assays by SRM approach have been developed for simultaneous quantification of multiple proteins. [80] These latter mass spectrometry-based assays could replace ELISA assays for clinical analysis in future.
SALIVARY BIOMARKERS IN CANCER
A number of recent studies have taken advantage of progress made in mass spectrometry to identify putative salivary biomarkers for early cancer diagnosis. [6, 81, 82, 83, 84] For example, saliva collected from 72 subjects (36 lung cancer patients; 36 controls) was analyzed by 2DE followed by mass spectrometry. [81] Of 253 proteins detected based on fold change, 30 proteins were identified. Amongst these proteins, haptoglobin, zincalpha-2-glycoprotein and human calprotectin were chosen for further validation by Western blot and ELISA. It is critical in biomarker discovery that changes in abundance of validated marker proteins are not only indicative of abundance between patient and control samples, but also correlate with alterations in biological functions which could be targeted for therapeutic interventions. For instance, human calprotectin, a complex of S100A8 and S100A9, expressed due to soluble factors released by lung tumors, acts as guide for adhesion and invasion of In addition to detecting salivary proteins as potential biomarkers, mass spectrometry can be used to identify and quantify different metabolites in saliva. For example, Sugimoto et al [89] performed a comprehensive study to identify salivary metabolites collected from 215 individuals (69 oral, 18 pancreatic and 30 breast cancer, 11 periodontal disease patients and 87 healthy controls). In this study, use of capillary electrophoresis couple time-of-flight mass spectrometry (CE-TOF-MS) resulted in the confident identification of 57 metabolites (e.g. pyrroline, leucine, valine and tryptophan) related to individual disease. Receiver operating characteristics curves used to discriminate between disease and control subjects were 0.865 for oral cancer, 0.973 for breast cancer, 0.993 for pancreatic cancer and 0.969 for periodontal diseases.
CONCLUSION AND FUTURE DIRECTIONS
Cancer is complex and heterogeneous disease, thus biomarker discovery requires a concerted effort by clinical researchers using multidisciplinary diagnostic approach. It is critical to look beyond the traditional diagnostic bodyfluid, blood, at other fluids such as saliva. Recent advances in the field of salivary proteomics and proteomic technologies using sensitive and specific quantitative mass spectrometry hold promise for validating candidate protein biomarkers. By mass spectrometry-based approach, we cannot only identify potential biomarkers but also protein isoforms, splice variants, more than 200 different posttranslational modifications and amino acid-relevant single-nucleotide polymorphism which may prove valuables as disease biomarkers.
